Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim ...
The "Inhalable Biologics Market Size, Share & Trends Analysis Report by Biologics (Peptides & Proteins, Monoclonal Antibodies, RNAi-Based Therapeutics), Application (Diabetes, Cancer), Dosage Form, ...
The "mRNA Vaccines Market by Technology Type, Route of Administration, Manufacturing Process, Vaccine Classification, Application Areas, End-User, Distribution Channel - Global Forecast 2025-2030" ...
4d
Imagine if antibodies, hormones for fertility, proteins like insulin, and vaccines could be swallowed instead of taken by ...
The cocktail design of vaccine, tried on mice by Chinese scientists, mitigates the progression of fatty plaque in arteries ...
Zacks Investment Research on MSN9d
BEAM Down Despite Positive Initial Data From Genetic Disorder StudyBeam Therapeutics Inc. BEAM announced positive initial safety and efficacy data from a phase I/II study, which is evaluating ...
Dealbreaker on MSN9d
Beam Base Editor’s Early Data in Rare Liver Disease Tee Up $500M Stock Sale in Tough MarketA Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has ...
Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable ...
It has been five years since the world was blown into the tumult of a lethal pandemic. Back then, deserted streets and ...
H.C. Wainwright analyst Patrick Trucchio reiterates a Buy rating and $80 price target on Beam Therapeutics (BEAM) shares after the company ...
An international research project led by the University of Nebraska-Lincoln aims to transform the future of food by driving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback